256 related articles for article (PubMed ID: 24664997)
1. [Dry powder inhalers in cystic fibrosis].
Steinkamp G
Pneumologie; 2014 Jun; 68(6):378-85. PubMed ID: 24664997
[TBL] [Abstract][Full Text] [Related]
2. Inhaled antibiotics: dry or wet?
Tiddens HA; Bos AC; Mouton JW; Devadason S; Janssens HM
Eur Respir J; 2014 Nov; 44(5):1308-18. PubMed ID: 25323242
[TBL] [Abstract][Full Text] [Related]
3. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
4. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
Westerman EM; Heijerman HG; Frijlink HW
Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
[TBL] [Abstract][Full Text] [Related]
5. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
Nolan K; Knight H; Clark P
Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs.
Kukut Hatipoglu M; Hickey AJ; Garcia-Contreras L
Int J Pharm; 2018 Oct; 549(1-2):306-316. PubMed ID: 30077761
[TBL] [Abstract][Full Text] [Related]
7. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
8. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
9. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
10. Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB
Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
Uttley L; Harnan S; Cantrell A; Taylor C; Walshaw M; Brownlee K; Tappenden P
Eur Respir Rev; 2013 Dec; 22(130):476-86. PubMed ID: 24293463
[TBL] [Abstract][Full Text] [Related]
12. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
13. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
14. Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?
Uttley L; Tappenden P
Curr Opin Pulm Med; 2014 Nov; 20(6):607-12. PubMed ID: 25221853
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
16. Effect of inhaled dry powder mannitol on mucus and its clearance.
Daviskas E; Rubin BK
Expert Rev Respir Med; 2013 Feb; 7(1):65-75. PubMed ID: 23362816
[TBL] [Abstract][Full Text] [Related]
17. [Inhaled treatments in cystic fibrosis: what's new in 2013?].
Dubus JC; Bassinet L; Chedevergne F; Delaisi B; Desmazes-Dufeu N; Reychler G; Vecellio L;
Rev Mal Respir; 2014 Apr; 31(4):336-46. PubMed ID: 24750953
[TBL] [Abstract][Full Text] [Related]
18. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
19. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
[TBL] [Abstract][Full Text] [Related]
20. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
Mordasini C; Aebischer CC; Schoch OD
Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
